top of page
Browse by category
Search
ReShape Lifesciences provides merger update with Vyome Therapeutics
ReShape Lifesciences and Vyome Therapeutics have provided an update on the definitive merger agreement under which ReShape and Vyome will...
Variant Bio and Novo Nordisk sign multi-year research partnership to discover novel targets for metabolic disease
Variant Bio has announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the treatment of metabolic...
Rhythm gains expanded indication for IMCIVREE (setmelanotide) for patients as young as 2 years old
Rhythm Pharmaceuticals has received an expanded indication for IMCIVREE (setmelanotide) to include children as young as 2 years old to...
Zepbound (tirzepatide) is the first and only FDA approved prescription medicine for moderate-to-severe OSA in adults with obesity
The FDA has approved Eli Lilly and Company’s Zepbound (tirzepatide) as the first and only prescription medicine for adults with...
BioAge axes STRIDES trial evaluating azelaprag in combination with tirzepatide for the treatment of obesity
BioAge Labs is to discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag as monotherapy and in...
Introducing XNY Medical’s next-generation ENDO NOVA Powered Stapler
Bariatric News talked to Dr Jassim Fakhro, Senior Consultant in General, Metabolic, Bariatric and Robotic Surgery, Vice President of the...
LUCIDITY trial to assess Avexitide in post-bariatric hypoglycaemia patients
Amylyx Pharmaceuticals plans to initiate a Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class...
Surgical staplers market to reach US$7.29 billion by 2029
The global surgical staplers market is projected to reach US$7.29 Billion by 2029 from US$5.15 billion in 2024 at a compound annual...
Allurion launches AllurionMeds first AI-native compounded GLP-1 program
Allurion Technologies has launched AllurionMeds, a unique offering to patients that combines affordable and accessible weight loss...
Laekna and Eli Lilly to develop ActRIIA antibody for muscle-preserving weight loss in obesity
Laekna Therapeutics has entered a clinical collaboration with Eli Lilly to accelerate the development of LAE102, a novel Activin Receptor...
Browse by tag
bottom of page